Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.